WO1993004034A1 - Modification cristalline d'hydrochlorure de 2-dimethylaminoethyle ether d'acide n-butyl-amino benzoique, son procede d'obtention et preparation pharmaceutique d'anesthesie de l'×il basee sur celui-ci - Google Patents

Modification cristalline d'hydrochlorure de 2-dimethylaminoethyle ether d'acide n-butyl-amino benzoique, son procede d'obtention et preparation pharmaceutique d'anesthesie de l'×il basee sur celui-ci Download PDF

Info

Publication number
WO1993004034A1
WO1993004034A1 PCT/SU1991/000168 SU9100168W WO9304034A1 WO 1993004034 A1 WO1993004034 A1 WO 1993004034A1 SU 9100168 W SU9100168 W SU 9100168W WO 9304034 A1 WO9304034 A1 WO 9304034A1
Authority
WO
WIPO (PCT)
Prior art keywords
anesthesia
eφiρa
hydrochloride
κislοτy
eye
Prior art date
Application number
PCT/SU1991/000168
Other languages
English (en)
Russian (ru)
Inventor
Nikolai Borisovich Leonidov
Original Assignee
Vremenny Mezhotraslevoi Nauchno-Tekhnichesky Kollektiv 'bioeffekt'
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vremenny Mezhotraslevoi Nauchno-Tekhnichesky Kollektiv 'bioeffekt' filed Critical Vremenny Mezhotraslevoi Nauchno-Tekhnichesky Kollektiv 'bioeffekt'
Priority to CA002091686A priority Critical patent/CA2091686C/fr
Priority to EP91914958A priority patent/EP0553351B1/fr
Priority to JP3514607A priority patent/JPH0753703B2/ja
Priority to US07/958,106 priority patent/US5403951A/en
Priority to DE59107171T priority patent/DE59107171D1/de
Priority to PCT/SU1991/000168 priority patent/WO1993004034A1/fr
Priority to AU84316/91A priority patent/AU647824B2/en
Priority claimed from CA002091686A external-priority patent/CA2091686C/fr
Publication of WO1993004034A1 publication Critical patent/WO1993004034A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C07C227/42—Crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions

Definitions

  • the melting unit of the indicated modifications lies in the range from 147 to 5 ° C. In this process, the smelting process provides for the proper investigation of the two endothermic processes.
  • the claimed new crystalline modifica- tion is indicated on the 20th year of the connection, an application in the industry is found.
  • a medicament for eye anesthesia containing a valid substance and a pharmaceutical product, is hereby approved by the invention.
  • - 6 Rapid 2-dimethylamine-ethyl ester Acids in quantities of 0.05 to 0.5 wt.%.
  • the claimed one is more than 0.1%.
  • the claimed product is beneficial in the use of methyl cellulose.
  • the claimed product has a high methanesthesia of 10 with increased activity, practically does not cause adverse effects.
  • the distinction is known to the crystalline modifica- tions of it, which is resolvable in the case of refrigerators.
  • the first water treatment of the claimed modification has a value of ⁇ in the range of 4.5–6.0.
  • the declared substances are hydrochloride 2-dimethyl amine and oxybutyl acetate.
  • Measurement of retention time was carried out at a high-efficient cartridge with a non-polar liquid phase 5 at a gas circuit.
  • the length of the column is 30 m; the velocity of the carrier gas (helium) is 40 cm / min. Measurements were made at temperatures of 220, 230, 240 ° ⁇ . The results shown in Table 2 show the identity of the time of keeping the known and declared by me crystalline modification of the indicated connection. The data provided allows you to make a conclusion that the claimed crystalline mod- ification has a chemical compound of the indicated connection.
  • Table 2 15 Gas Names of a ⁇ metastable containment of the known and claimed crystalline modification of 2-dimethylamine ethyl hydrogen acid /
  • the claimed new crystalline modification of the indicated connection in this area is characterized only by weakly expressed areas of 84, 58 and 39 cm.
  • the local anesthetic activity of the application has been studied.
  • the claimed substance is 0.25 4 20.8 + 0.7 32.1 + 1.7
  • the claimed substance is 0.3 4 8.0 + 1.5 55.2 + 1.7
  • Me The preparation is part-time. For the sake of business,% of the patient is anesthetized.
  • P ⁇ i is ⁇ lz ⁇ vanii 0.1% -n ⁇ g ⁇ ⁇ as ⁇ v ⁇ a zayavlyaem ⁇ g ⁇ Yu vesches ⁇ va ⁇ d ⁇ lzhi ⁇ eln ⁇ s ⁇ ⁇ ln ⁇ y anes ⁇ ezii ⁇ zv ⁇ lila ⁇ - ves ⁇ i only ⁇ i e ⁇ a ⁇ a ⁇ ya ⁇ ie ⁇ a ⁇ n ⁇ y ⁇ e ⁇ adii ⁇ e ⁇ a ⁇ mii, ⁇ es ⁇ ⁇ azme ⁇ u, nad ⁇ ezy ⁇ e ⁇ i ⁇ e ⁇ ii ⁇ g ⁇ vitsy and nad ⁇ ezy d ⁇ tsen ⁇ aln ⁇ y ⁇ iches ⁇ y z ⁇ ny.
  • ⁇ ⁇ ezul ⁇ a ⁇ e ⁇ vedenny ⁇ is ⁇ y ⁇ any m ⁇ zhn ⁇ sdela ⁇
  • the data provided are indicative of the fact that the claimed crystalline modifica- tion of the substance in question is causing an increased level of local anesthesia.
  • the indicated properties will significantly reduce the cost of the preparation by increasing its therapeutic efficiency.
  • the claimed crystalline modification of the indicated compound, according to the invention, ' is a 5 active substance for the treatment of anesthesia of the eyes.
  • the inventive pharmaceutical product contains active substance in quantities of 0.05 to 0.5 wt. and an easy-to-use ophthalmic drug suitable for the eye droplet.
  • it can contain any commercially available alkyl-0 cellulose in quantities of 0.1 to 0.75 wt.%, In particular, viable for cellulose.
  • the concentration of active substances is determined by the fact that in the indicated range of concentrations, there is a high incidence of non-hazardous substances.
  • the inventive medicinal product can contain any alkaline industrial cellulose (methyl, ethyl, p- - 16 - sawing and tapping), for the most part, they cause an increase in the viscosity of the droplet, which makes the most efficient use of the active material.
  • alkaline industrial cellulose methyl, ethyl, p- - 16 - sawing and tapping
  • a well-known product active substance 0.25 sodium chloride 0.9 water distilled to 100 13.4 + 2.0 15.3 + 2.0 Turn the """ eyes to stop moving
  • active substance 1.0 sodium chloride 0.9 water distilled to 100 13.0 + 1.0 48.0 + 3.8 Increased volatility and maturity
  • Declared product active material 0.1 sodium halide 0.9 water distilled to 100 12.7 + 1.5 13.4 + 3.3 Not noted - 18 -
  • Option 2 was used for ophthalmic anesthesia in 28 patients. This product was stored
  • Option 3 is used for ophthalmic anesthesia in 80 patients. Castor also forgotten one
  • the inventive drug for eye anesthesia provides a convenient, clear, colorless liquid with a pH of 4.3-6.8. - 20 - Prepares the claimed preparation using a well-known technique.
  • the inventive device is protected at a temperature of 25 ° C in a protected place. ⁇ ⁇ for 12 months.
  • the substance claimed is a new product - a new crystalline modification of a 2-dimethylamine-hydrogen hydrochloride ester 20 n ⁇ y ⁇ isl ⁇ y ⁇ luchayu ⁇ ⁇ u ⁇ em ⁇ lazhdeniya ⁇ as ⁇ v ⁇ a ⁇ lim ⁇ - n ⁇ y ⁇ my u ⁇ azann ⁇ g ⁇ s ⁇ edineniya in v ⁇ de or ⁇ ganiches ⁇ m ⁇ as ⁇ v ⁇ i ⁇ ele or i ⁇ mixture ⁇ ladagen ⁇ m s ⁇ s ⁇ s ⁇ yu not lower than 8 ° C / min d ⁇ ⁇ ln ⁇ y eg ⁇ ⁇ is ⁇ illizatsii with ⁇ sleduyuschim ⁇ deleniem ⁇ luchenny ⁇ ⁇ is ⁇ all ⁇ v and i ⁇ sush ⁇ y.
  • any material may be used; it is possible to reduce the temperature of the refrigerant and the coolant should be at least 8 ° C / min.
  • ⁇ aib ⁇ lee ⁇ imalnym vesches ⁇ v ⁇ m is ⁇ lzuemym in ⁇ aches ⁇ ve ⁇ ladagen ⁇ a, yavlyae ⁇ sya zhid ⁇ y az ⁇ , is ⁇ lz ⁇ vanie ⁇ g ⁇ ⁇ zv ⁇ lyae ⁇ ⁇ vysi ⁇ 0 vy ⁇ d tselev ⁇ g ⁇ ⁇ , on account ⁇ u__ ⁇ a bys ⁇ g ⁇ us ⁇ an ⁇ vleniya and dalneysheg ⁇ ⁇ dde ⁇ zhaniya ne ⁇ b ⁇ dim ⁇ y s ⁇ s ⁇ i ⁇ lal ⁇ tseniya.
  • Cooling of the original product is indicated by a refrigerant, due to the Improvement of the process of industrialization and the cooling rate below 8 ° C / min does not allow to receive the declared new critical mod- uation.
  • - 21 The business of cooling is not limited. With the maximum accessible cooling rate, the original processing unit is equipped with a new cooling system. 5 The refrigeration process is carried out in water or in any other kind of industrial solvent, or in a mixture thereof, in direct discharged material.
  • the optimal solvents, in addition to the well-disposed raw materials, are water and ethanol. With this, the largest yield of the target 10 products is achieved.
  • the claimed substance can be independently obtained from the center of the source material in the factory.
  • the yield of the target product is 96.2 wt.%. 5 Received material with melting point 148.6+
  • Example 15 Example 4
  • Example II The process is similar to that described in Example I, and this drying is carried out in freeze-drying at a pressure of 10 mm ⁇ .st.
  • Example 5 The yield of the target product was 96.8 wt.%. 20 The resulting material is similar to that of Example I. Example 5
  • Example 6 Drying at a pressure of 10 mm ⁇ .st. The target product was 95.6 wt.%. 0 Received material for all parameters complies with material I of Example I with a melting point of 148.6 + 0.3 ° C with a single endothermic effect.
  • Example 6
  • Example 7 The process is carried out in a similar manner to Example 5, and, moreover, this is a 5th center of the source material in ethanol 50% by weight. The yield of the target product is 97.0 wt.%. The resulting material has the same characteristics as Example I. - 23 - Example 7
  • Example II The process is carried out similarly to Example 5 with a cooling rate of 300 ° C / min.
  • the target product yield was 98.2 wt.%.
  • the resulting material is similar to those of 5 Example I.
  • Example 5 The process is carried out in a similar manner to Example 5, and this is done in a freeze dryer at a pressure of 10 mm ⁇ .st. The yield of the target product was 96.3 wt.%.
  • Example 5 It takes 500 ml of a 10-milliliter of the original material in a mixture of water-ethanol (1: 1). The process is carried out in a similar manner to Example 5. The yield of the target product is 96.0 wt. . 15 Received material has the same characteristics as Example I.

Abstract

Une nouvelle modification cristalline d'hydrochlorure de 2-diméthylaminoéthyle éther d'acide n-butyl-amino benzoïque est caractérisé par un effet de fusion endothermique à une température de 148,6° ± 0,3 °C, et par les valeurs de distances interplans d et d'intensité relative de réflexes (I). Un procédé d'obtention de ladite substance consiste à refroidir la solution d'hydrochlorure de 2-diméthylaminoéthyle éther n-butyl-amino benzoïque de forme polymorphe dans l'eau, dans un solvant organique ou dans leur mélange, au moyen d'un agent de refroidissement, à une vitesse non inférieure à 8 °C/mn jusqu'à sa cristallisation totale, puis à sécher les cristaux ainsi obtenus. La substance de l'invention présente des propriétés d'anesthésie locale et constitue un agent actif d'une préparation pharmaceutique d'anesthésie de l'÷il (la teneur en substance active étant comprise entre 0,05 et 0,5 % en poids).
PCT/SU1991/000168 1991-04-30 1991-08-19 Modification cristalline d'hydrochlorure de 2-dimethylaminoethyle ether d'acide n-butyl-amino benzoique, son procede d'obtention et preparation pharmaceutique d'anesthesie de l'×il basee sur celui-ci WO1993004034A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002091686A CA2091686C (fr) 1991-08-19 1991-08-19 Modification du reseau cristallin du chlorhydrure de 2-dimethylaminoethyl-n-butylaminobenzoate, methode d'obtention et preparation pharmaceutique pour l'anesthesie oculaire ainsi obtenue
EP91914958A EP0553351B1 (fr) 1991-08-19 1991-08-19 Modification cristalline d'hydrochlorure de 2-dimethylaminoethyle ether d'acide n-butyl-amino benzoique, son procede d'obtention et preparation pharmaceutique d'anesthesie de l'oeil basee sur celui-ci
JP3514607A JPH0753703B2 (ja) 1991-08-19 1991-08-19 塩酸２―ジメチルアミノエチル―ｎ―ブチルアミノベンゾエートの結晶変形、その製造方法、およびそれを基剤とした眼麻酔用医薬製剤
US07/958,106 US5403951A (en) 1991-04-30 1991-08-19 Crystalline modification of 2-dimethylaminoethyl-n-butylaminobenzoate hydrochloride, method for production thereof and pharmaceutical preparation for anaesthesia of eyes, based thereon
DE59107171T DE59107171D1 (de) 1991-08-19 1991-08-19 Kristalline Modifikation des Hydrogenchlorids des 2-Dymethylaminoäthylesters der n-Butylamino-BenzoesÄure, Verfahren zur Herstellung dieser Modifikation und ArzneimittelprÄparat zur Anästhesie der Augen auf Ihrer Basis
PCT/SU1991/000168 WO1993004034A1 (fr) 1991-08-19 1991-08-19 Modification cristalline d'hydrochlorure de 2-dimethylaminoethyle ether d'acide n-butyl-amino benzoique, son procede d'obtention et preparation pharmaceutique d'anesthesie de l'×il basee sur celui-ci
AU84316/91A AU647824B2 (en) 1991-08-19 1991-08-19 Crystalline modification of hydrochloride of 2-dimethylaminoethyl ether of N-butylamino benzoic acid, method of obtaining it and pharmaceutical preparation for anesthesia of the eye based thereupon

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002091686A CA2091686C (fr) 1991-08-19 1991-08-19 Modification du reseau cristallin du chlorhydrure de 2-dimethylaminoethyl-n-butylaminobenzoate, methode d'obtention et preparation pharmaceutique pour l'anesthesie oculaire ainsi obtenue
PCT/SU1991/000168 WO1993004034A1 (fr) 1991-08-19 1991-08-19 Modification cristalline d'hydrochlorure de 2-dimethylaminoethyle ether d'acide n-butyl-amino benzoique, son procede d'obtention et preparation pharmaceutique d'anesthesie de l'×il basee sur celui-ci

Publications (1)

Publication Number Publication Date
WO1993004034A1 true WO1993004034A1 (fr) 1993-03-04

Family

ID=25675990

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SU1991/000168 WO1993004034A1 (fr) 1991-04-30 1991-08-19 Modification cristalline d'hydrochlorure de 2-dimethylaminoethyle ether d'acide n-butyl-amino benzoique, son procede d'obtention et preparation pharmaceutique d'anesthesie de l'×il basee sur celui-ci

Country Status (1)

Country Link
WO (1) WO1993004034A1 (fr)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
M.D. MASHKOVSKY; Lekarstvennye sredstva, vol. I, 1986, Meditsina (Moscow), pages 325-328, 332-333. *
M.V. RUBTSOV et al. "Sinteticheskie khimikofarmatsevticheskie preparaty", 1971 Meditsina (Moscow), pages 74-77. *
MEZHDUNARODNAYA FARMAKOPEYA, vol. 3 "Spetsifikatsiya dlya kontrolya kachestva farmatsevticheskikh preparatov", 1990, voz (Geneva), pages 356-358. *
See also references of EP0553351A4 *
Thermochimica Acta vol. 153, 1989, Elsevier Science Publishers B.V. (Amsterdam), pages 11-26, R. CURINI et al. "Thermal analytical techniques applied to the narcotic field: cocaine analysis". *

Similar Documents

Publication Publication Date Title
US4690823A (en) Ibuprofen-containing soft gelatin capsules and process for preparing same
US4814326A (en) Pharmaceutical compositions based on diphosphonates for the treatment of arthrosis and osteoarthritis
EP0271709B1 (fr) Sel du diclofenac avec une base organique cyclique et compositions pharmaceutiques le contenant
KR100196212B1 (ko) 니코란딜을 함유하는 안정한 약제조성물
US2304104A (en) Therapeutical zinc peroxide
US3361769A (en) Bi-metallic salts of gluconic, glucuronic, or galacturonic acid
EP0553351A4 (fr)
WO1993004034A1 (fr) Modification cristalline d'hydrochlorure de 2-dimethylaminoethyle ether d'acide n-butyl-amino benzoique, son procede d'obtention et preparation pharmaceutique d'anesthesie de l'×il basee sur celui-ci
EP0944612B1 (fr) Hydrate de n-(4-acetyl-1-piperazinyl)-4-fluorobenzamide
US3734734A (en) Deproteinizing protein-containing solutions
US4698361A (en) Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same
PODWISSOTZKI ON THE ACTIVE CONSTITUENTS OF PODOPHYLLIN.
US2601204A (en) Process of lowering blood prothrombin level and lengthening clotting time with methylenebis-hydroxy coumarin
US3839317A (en) Digoxin complexes
US2259492A (en) Therapeutic preparation of bismuth and method of preparing same
US2312195A (en) Salts of dextro-ascorbic acid and method of preparing same
US3847973A (en) Doxycycline acetylcysteineate
US2193165A (en) Citrates of procaine and method for their production
US3929996A (en) Pharmaceutical compositions containing a digoxin complex
US2395069A (en) Preparations of arsenic and antimony
WO1995005361A1 (fr) PROCEDE D'OBTENTION D'UNE MODIFICATION η-CRISTALLINE PHYSIQUEMENT STABLE DE PARA-AMINOBENZENE SULFANILAMIDE
US3715437A (en) Method of achieving an antipeptic action in animals with bimetallic compounds
Drummond A Case of Pernicious Anæmia Treated with Bone Marrow
Barger et al. Note on a supposed soluble toxin, produced in artificial culture by the bacillus of malignant oedema
FR2463124A1 (fr) Acides 2-amino-3-(alkylthiobenzoyl)-phenylacetiques et derives, et leur utilisation comme anti-inflammatoires, analgesiques, et inhibant l'agglomeration des plaquettes sanguines

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1991914958

Country of ref document: EP

AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2091686

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1991914958

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1991914958

Country of ref document: EP